Efficacy and perioperative effect of docetaxel plus oxaliplatin and S-1 in treating advanced gastric cancer / 中国肿瘤临床

ABSTRACT

Objective: This study investigates the effect of docetaxel + oxaliplatin + S-1 (DOS program) in treating advanced gastric cancer and surgical safety assessment. Methods: Fifty patients with advanced gastric cancer admitted to the Department of Gastrointestinal Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University between January 2011 and May 2012 were enrolled in this study. These patients were randomized into the observation arm (n=25) and the control group (n=25). The observer group was administered three cycles of chemotherapy using a DOS program before surgical treatment, whereas the control group underwent surgery. Results: Compared with the control group, the clinical response rate (64.0%), D2 lymph node dissection rate (88.0% vs. 64.0%), and R0 resection rate (92.0%vs. 68.0%) in the observation group were significantly higher (P0.05). The patients exhibited good tolerance to chemotherapy, with bone marrow suppression and gastrointestinal reactions as the main adverse effects. Conclusion:The DOS program is a highly efficient, advanced gastric cancer neoadjuvant chemotherapy. The program can improve patient survival and has good patient tolerance and compliance, good peri-operative safety, high R0 resection rate, and low postoperative lymph node metastasis rate.